Top

Published in:

Open Access 01-04-2018

How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review

Authors: Cornelie D. Andela, Daniel J. Lobatto, Alberto M. Pereira, Wouter R. van Furth, Nienke R. Biermasz

Published in: Pituitary | Issue 2/2018

Abstract

After treatment for a non-functioning pituitary adenoma (NFA) health-related quality of life (HR-QoL) improves considerably. However, the literature about the normalization of HR-QoL after treatment is inconclusive. Some researchers described a persistently decreased HR-QoL compared to reference data, while others did not. Considering this variety in observed HR-QoL outcomes, the aim of the present review was to provide a literature overview of health outcomes in patients with a NFA, using a conceptual HR-QoL model. A concrete conceptualization of the health outcomes of patients with a NFA can be helpful to understand the observed variety in HR-QoL outcomes and to improve clinical care and guidance of these patients. For this conceptualization, the Wilson and Cleary model was used. This model has a biopsychosocial character and has been validated in several patient populations. In the present review, health outcomes of patients with a NFA were described at each stage of the model e.g. biological and physiological variables, symptom status, functional status, general health perceptions and overall HR-QoL. The Wilson–Cleary model elucidates that elements at each stage of the model can contribute to the impairment in HR-QoL of patients with a NFA, which explains the reported variety in the literature. Furthermore, by applying the model, potential interventions targeting these elements can be identified. While optimal biomedical treatment has always been the focus, it is clearly not sufficient for good HR-QoL in patients with a NFA. Further improvement of HR-QoL should be supported by a pituitary specific care trajectory, including psychosocial care (e.g. self-management training), to beneficially affect characteristics of the patient and the (healthcare) environment, with the utmost goal to optimize HR-QoL in patients after treatment.

Karavitaki N (2012) Prevalence and incidence of pituitary adenomas. Ann Endocrinol (Paris) 73(2):79–80. https://doi.org/10.1016/j.ando.2012.03.039 CrossRef

Javorsky BR, Aron DC, Findling JW, Tyrrell JB (2011) Hypothalamus & pituitary gland. In: Gardner DG, Shoback D (eds) Greenspan’s basic & clinical endocrinology. McGraw-Hill Companies, Singapore, pp 65–114

Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire UK). Clin Endocrinol (Oxf) 72(3):377–382. https://doi.org/10.1111/j.1365-2265.2009.03667.x CrossRef

Andela CD, Scharloo M, Pereira AM, Kaptein AA, Biermasz NR (2015) Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 18(5):752–776. https://doi.org/10.1007/s11102-015-0636-7 CrossRefPubMed

Dekkers OM, van der Klaauw AA, Pereira AM, Biermasz NR, Honkoop PJ, Roelfsema F, Smit JW, Romijn JA (2006) Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 91(9):3364–3369. https://doi.org/10.1210/jc.2006-0003 CrossRefPubMed

Biermasz NR, Joustra SD, Donga E, Pereira AM van Duinen N, van Dijk M, van der Klaauw AA, Corssmit EPM, Lammers GJ, van Kralingen KW, van Dijk JG, Romijn JA (2011) Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality. J Clin Endocrinol Metab 96(5):1524–1532. https://doi.org/10.1210/jc.2010-2742 CrossRefPubMed

Capatina C, Christodoulides C, Fernandez A, Cudlip S, Grossman AB, Wass JA, Karavitaki N (2013) Current treatment protocols can offer a normal or near-normal quality of life in the majority of patients with non-functioning pituitary adenomas. Clin Endocrinol (Oxf) 78(1):86–93. https://doi.org/10.1111/j.1365-2265.2012.04449.x CrossRef

Nielsen EH, Lindholm J, Laurberg P, Bjerre P, Christiansen JS, Hagen C, Juul S, Jorgensen J, Kruse A, Stochholm K (2007) Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary 10(1):67–73. https://doi.org/10.1007/s11102-007-0018-x CrossRefPubMed

Wilson IB, Cleary PD (1995) Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273(1):59–65CrossRefPubMed

10.

Engel GL (1977) The need for a new medical model: a challenge for biomedicine. Science 196(4286):129–136CrossRefPubMed

11.

McGee H, Ring L (2010) Quality of Life. In: French D, Vedhara K, Kaptein AA, Weinman J (eds) Health psychology. BPS Blackwell, Chichester, pp 329–344

12.

Schipper H, Clinch JJ, Olweny CLM (1990) Quality of life studies: definitions and conceptual issues. In: Spilker B (ed) Quality of life assessments in clinical trials. Raven Press, Ltd, New York, p 16

13.

Sousa KH, Kwok OM (2006) Putting Wilson and Cleary to the test: analysis of a HRQOL conceptual model using structural equation modeling. Qual Life Res 15(4):725–737. https://doi.org/10.1007/s11136-005-3975-4 CrossRefPubMed

14.

Kanters TA, Redekop WK, Rutten-Van Molken MP, Kruijshaar ME, Gungor D, van der Ploeg AT, Hakkaart L (2015) A conceptual disease model for adult Pompe disease. Orphanet J Rare Dis 10, 112. https://doi.org/10.1186/s13023-015-0334-6 CrossRefPubMedPubMedCentral

15.

Shahrbanian S, Duquette P, Ahmed S, Mayo NE: Pain acts through fatigue to affect participation in individuals with multiple sclerosis. Qual Life Res 25(2), 477–491 (2016). https://doi.org/10.1007/s11136-015-1098-0 CrossRefPubMed

16.

Mayo NE, Scott SC, Bayley M, Cheung A, Garland J, Jutai J, Wood-Dauphinee S (2015) Modeling health-related quality of life in people recovering from stroke. Qual Life Res 24(1):41–53. https://doi.org/10.1007/s11136-013-0605-4 CrossRefPubMed

17.

Lecumberri B, Estrada J, Garcia-Uria J, Millan I, Pallardo LF, Caballero L, Lucas T (2015) Neurocognitive long-term impact of two-field conventional radiotherapy in adult patients with operated pituitary adenomas. Pituitary 18(6):782–795. https://doi.org/10.1007/s11102-015-0653-6 CrossRefPubMed

18.

BijnierNET (2016) Stressinstructies. http://www.bijniernet.nl/

19.

Staufenbiel SM, Andela CD, Manenschijn L, Pereira AM, van Rossum EF, Biermasz NR (2015) Increased hair cortisol concentrations and BMI in patients with pituitary-adrenal disease on hydrocortisone replacement. J Clin Endocrinol Metab 100(6):2456–2462. https://doi.org/10.1210/jc.2014-4328 CrossRefPubMed

20.

Andela CD, Staufenbiel SM, Joustra SD, Pereira AM, van Rossum EF, Biermasz NR (2016) Quality of life in patients with adrenal insufficiency correlates stronger with hydrocortisone dosage, than with long-term systemic cortisol levels. Psychoneuroendocrinology 72:80–86. https://doi.org/10.1016/j.psyneuen.2016.06.015 CrossRefPubMed

21.

Wolf A, Goncalves S, Salehi F, Bird J, Cooper P, Van Uum S, Lee DH, Rotenberg BW, Duggal N (2016) Quantitative evaluation of headache severity before and after endoscopic transsphenoidal surgery for pituitary adenoma. J Neurosurg 124(6):1627–1633. https://doi.org/10.3171/2015.5.jns1576 CrossRefPubMed

22.

Little AS, Kelly DF, Milligan J, Griffiths C, Prevedello DM, Carrau RL, Rosseau G, Barkhoudarian G, Jahnke H, Chaloner C, Jelinek KL, Chapple K, White WL (2015) Comparison of sinonasal quality of life and health status in patients undergoing microscopic and endoscopic transsphenoidal surgery for pituitary lesions: a prospective cohort study. J Neurosurg 123(3):799–807. https://doi.org/10.3171/2014.10.jns14921 CrossRefPubMed

23.

Wang S, Chen Y, Li J, Wei L, Wang R (2015) Olfactory function and quality of life following microscopic endonasal transsphenoidal pituitary surgery. Medicine 94(4):e465. https://doi.org/10.1097/md.0000000000000465 CrossRefPubMedPubMedCentral

24.

Andela CD, Niemeijer ND, Scharloo M, Tiemensma J, Kanagasabapathy S, Pereira AM, Kamminga NG, Kaptein AA, Biermasz NR (2014) Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL. Pituitary 18(1):86–100. https://doi.org/10.1007/s11102-014-0561-1 CrossRef

25.

Joustra SD, Thijs RD, van den Berg R, van Dijk M, Pereira AM, Lammers GJ, van Someren EJ, Romijn JA, Biermasz NR (2014) Alterations in diurnal rhythmicity in patients treated for nonfunctioning pituitary macroadenoma: a controlled study and literature review. Eur J Endocrinol 171(2):217–228. https://doi.org/10.1530/eje-14-0172 CrossRefPubMed

26.

Romijn JA, Smit JW, Lamberts SW (2003) Intrinsic imperfections of endocrine replacement therapy. Eur J Endocrinol 149(2):91–97CrossRefPubMed

27.

Romijn JA (2016) Pituitary diseases and sleep disorders. Current opinion in endocrinology. diabetes obesity 23(4):345–351. https://doi.org/10.1097/med.0000000000000265

28.

Joustra SD, Kruijssen E, Verstegen MJ, Pereira AM, Biermasz NR (2014) Determinants of altered sleep-wake rhythmicity in patients treated for nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 99(12):4497–4505. https://doi.org/10.1210/jc.2014-2602 CrossRefPubMed

29.

van der Klaauw AA, Dekkers OM, Pereira AM, van Kralingen KW, Romijn JA (2007) Increased daytime somnolence despite normal sleep patterns in patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92(10):3898–3903. https://doi.org/10.1210/jc.2007-0944 CrossRefPubMed

30.

Brummelman P, Elderson MF, Dullaart RP, van den Bergh AC, Timmer CA, van den Berg G, Koerts J, Tucha O, Wolffenbuttel BH, van Beek AP (2011) Cognitive functioning in patients treated for nonfunctioning pituitary macroadenoma and the effects of pituitary radiotherapy. Clin Endocrinol (Oxf) 74(4):481–487. https://doi.org/10.1111/j.1365-2265.2010.03947.x CrossRef

31.

Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJ, Wassenaar MJ, Middelkoop HA, Pereira AM, Romijn JA (2010) Subtle cognitive impairments in patients with long-term cure of Cushing’s disease. J Clin Endocrinol Metab 95(6):2699–2714. https://doi.org/10.1210/jc.2009-2032 CrossRefPubMed

32.

Noad R, Narayanan KR, Howlett T, Lincoln NB, Page RC (2004) Evaluation of the effect of radiotherapy for pituitary tumours on cognitive function and quality of life. Clin Oncol (R Coll Radiol) 16(4):233–237CrossRef

33.

van Beek AP, van den Bergh AC, van den Berg LM, van den Berg G, Keers JC, Langendijk JA, Wolffenbuttel BH (2007) Radiotherapy is not associated with reduced quality of life and cognitive function in patients treated for nonfunctioning pituitary adenoma. Int J Radiat Oncol Biol Phys 68(4):986–991. https://doi.org/10.1016/j.ijrobp.2007.01.017 CrossRefPubMed

34.

Peace KA, Orme SM, Thompson AR, Padayatty S, Ellis AW, Belchetz PE (1997) Cognitive dysfunction in patients treated for pituitary tumours. J Clin Exp Neuropsychol 19(1):1–6. https://doi.org/10.1080/01688639708403831 CrossRefPubMed

35.

Horne R (2003) Treatment perceptions and self-regulation. In: Cameron LD, Leventhal H (eds) The self-regulation of health and illness behaviour. Routledge, London, pp 138–183

36.

Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR (2011) Coping strategies in patients after treatment for functioning or nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 96(4):964–971. https://doi.org/10.1210/jc.2010-2490 CrossRefPubMed

37.

Sievers C, Ising M, Pfister H, Dimopoulou C, Schneider HJ, Roemmler J, Schopohl J, Stalla GK (2009) Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls. Eur J Endocrinol 160(3):367–373. https://doi.org/10.1530/EJE-08-0896 CrossRefPubMed

38.

Andela CD, Scharloo M, Ramondt S, Tiemensma J, Husson O, Llahana S, Pereira AM, Kaptein AA, Kamminga NG, Biermasz NR: The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary. Pituitary 19(3), 293–302 (2016). https://doi.org/10.1007/s11102-016-0707-4 CrossRefPubMedPubMedCentral

39.

Andela CD, Tiemensma J, Kaptein AA, Scharloo M, Pereira AM, Kamminga NGA, Biermasz NR (2017) The partner’s perspective of the impact of pituitary disease: looking beyond the patient. J Health Psychol. https://doi.org/10.1177/1359105317695427 PubMed

40.

Macht M, Gerlich C, Ellgring H, Schradi M, Rusinol AB, Crespo M, Prats A, Viemero V, Lankinen A, Bitti PE, Candini L, Spliethoff-Kamminga N, de Vreugd J, Simons G, Pasqualini MS, Thompson SB, Taba P, Krikmann U, Kanarik E (2007) Patient education in Parkinson’s disease: Formative evaluation of a standardized programme in seven European countries. Patient Educ Couns 65(2):245–252. https://doi.org/10.1016/j.pec.2006.08.005 CrossRefPubMed

41.

Bandura A (1986) Social foundations of thought and action: a social cognitive theory. Prentice-Hall, Inc., Englewood Cliffs

42.

Abubakari AR, Cousins R, Thomas C, Sharma D, Naderali EK (2016)Sociodemographic and clinical predictors of self-management among people with poorly controlled type 1 and type 2 diabetes: the role of illness perceptions and self-efficacy. J Diabetes Res. https://doi.org/10.1155/2016/6708164 PubMed

43.

Wilski M, Tasiemski T (2015) Illness perception, treatment beliefs, self-esteem, and self-efficacy as correlates of self-management in multiple sclerosis. Acta Neurol Scand 133(5):338–345. https://doi.org/10.1111/ane.12465 CrossRefPubMed

44.

Andela CD, Repping-Wuts H, Stikkelbroeck NMML., Pronk MC, Tiemensma J, Hermus AR, Kaptein AA, Pereira AM, Kamminga NGA, Biermasz NR (2017) Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial. Eur J Endocrinol 177(1), 59–72. https://doi.org/10.1530/EJE-16-1015 CrossRefPubMed

45.

Johnson MD, Woodburn CJ, Vance ML (2003) Quality of life in patients with a pituitary adenoma. Pituitary 6(2):81–87CrossRefPubMed

46.

Raappana A, Pirila T, Ebeling T, Salmela P, Sintonen H, Koivukangas J (2012) Long-term health-related quality of life of surgically treated pituitary adenoma patients: a descriptive study. ISRN Endocrinol. https://doi.org/10.5402/2012/675310 PubMedPubMedCentral

47.

Tanemura E, Nagatani T, Aimi Y, Kishida Y, Takeuchi K, Wakabayashi T (2012) Quality of life in nonfunctioning pituitary macroadenoma patients before and after surgical treatment. Acta Neurochir (Wien) 154(10):1895–1902. https://doi.org/10.1007/s00701-012-1473-3 CrossRef

48.

Page RC, Hammersley MS, Burke CW, Wass JA (1997) An account of the quality of life of patients after treatment for non-functioning pituitary tumours. Clin Endocrinol (Oxf) 46(4):401–406CrossRef

49.

Casanueva FF, Leal A, Koltowska-Haggstrom M, Jonsson P, Goth MI (2005) Traumatic brain injury as a relevant cause of growth hormone deficiency in adults: a KIMS-based study 54. Arch Phys Med Rehabil 86(3):463–468. https://doi.org/10.1016/j.apmr.2004.05.018 CrossRefPubMed

50.

Kreitschmann-Andermahr I, Poll EM, Reineke A, Gilsbach JM, Brabant G, Buchfelder M, Fassbender W, Faust M, Kann PH, Wallaschofski H (2008) Growth hormone deficient patients after traumatic brain injury–baseline characteristics and benefits after growth hormone replacement–an analysis of the German KIMS database. Growth Hormon IGF Res 18(6):472–478. https://doi.org/10.1016/j.ghir.2008.08.007 CrossRef

51.

Verhelst J, Kendall-Taylor P, Erfurth EM, Price DA, Geffner M, Koltowska-Haggstrom M, Jonsson PJ, Wilton P, Abs R (2005) Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab 90(8):4636–4643. https://doi.org/10.1210/jc.2005-0185 CrossRefPubMed

52.

Milian M, Honegger J, Gerlach C, Psaras T (2013) Health-related quality of life and psychiatric symptoms improve effectively within a short time in patients surgically treated for pituitary tumors–a longitudinal study of 106 patients. Acta Neurochir (Wien) 155(9):1637–1645CrossRef

53.

Li A, Liu W, Cao P, Zheng Y, Bu Z, Zhou T (2017) Endoscopic versus microscopic transsphenoidal surgery in the treatment of pituitary adenoma: a systematic review and meta-analysis. World Neurosurg 101:236–246. https://doi.org/10.1016/j.wneu.2017.01.022 CrossRefPubMed

54.

Lwu S, Edem I, Banton B, Bernstein M, Vescan A, Gentili F, Zadeh G (2012) Quality of life after transsphenoidal pituitary surgery: a qualitative study. Acta Neurochir 154(10):1917–1922. https://doi.org/10.1007/s00701-012-1455-5 CrossRefPubMed

55.

Svensson J, Finer N, Bouloux P, Bevan J, Jonsson B, Mattsson AF, Lundberg M, Harris PE, Koltowska-Haggstrom M, Monson JP (2007) Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Growth Hormon IGF Res 17(1):67–76. https://doi.org/10.1016/j.ghir.2006.11.002 CrossRef

56.

Giavoli C, Profka E, Verrua E, Ronchi CL, Ferrante E, Bergamaschi S, Sala E, Malchiodi E, Lania AG, Arosio M, Ambrosi B, Spada A, Beck-Peccoz P (2012) GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency. J Clin Endocrinol Metab 97(11):3983–3988. https://doi.org/10.1210/jc.2012-2477 CrossRefPubMed

57.

Hoybye C, Ragnarsson O, Jonsson PJ, Koltowska-Haggstrom M, Trainer P, Feldt-Rasmussen U, Biller BM (2010) Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing’s disease. Eur J Endocrinol 162(4):677–684. https://doi.org/10.1530/EJE-09-0836 CrossRefPubMed

Title: How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review
Authors: Cornelie D. Andela
Daniel J. Lobatto
Alberto M. Pereira
Wouter R. van Furth
Nienke R. Biermasz
Publication date: 01-04-2018
Publisher: Springer US
Published in: Pituitary / Issue 2/2018
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-017-0860-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Management of nonfunctioning pituitary adenomas (NFAs): observation

Prognostic factors of regrowth in nonfunctioning pituitary tumors

Non-functioning pituitary adenomas, not all the same and certainly not boring!

Management of nonfunctioning pituitary tumors: radiotherapy

Pathogenesis of non-functioning pituitary adenomas

Silent corticotroph adenomas

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page